{"status": "ok", "totalResults": 108, "articles": [{"source": {"id": "al-jazeera-english", "name": "Al Jazeera English"}, "author": "Al Jazeera", "title": "India bans hundreds of combination drugs", "description": "Government outlaws 328 drugs to combat medicine misuse and rising antibiotic resistance.", "url": "https://www.aljazeera.com/news/2018/09/india-bans-hundreds-combination-drugs-180913085744857.html", "urlToImage": "https://www.aljazeera.com/mritems/Images/2018/9/13/21551545769d41bbae79f1cdcdbd2ee5_18.jpg", "publishedAt": "2018-09-13T10:39:01Z", "content": "The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Indian governm\u2026 [+1954 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "PTI", "title": "Centre bans 328 combination drugs in setback for pharma companies", "description": "The president of the Indian Drug Manufacturers' Association said the order would have an impact on a market worth an estimated 16 billion rupees a year for such drugs, which are produced by both small and large pharma companies.", "url": "https://indianexpress.com/article/business/business-others/centre-bans-328-combination-drugs-in-setback-for-pharma-companies-5354509/", "urlToImage": "https://images.indianexpress.com/2017/11/drugs-7592.jpg?w=759", "publishedAt": "2018-09-13T09:13:42Z", "content": "By: PTI | New Delhi | Published: September 13, 2018 2:43:42 pm Combination drugs are used to improve patients\u2019 compliance, as it is easier to get patients to take one drug rather than several. (Representational image) The Indian government has banned 328 comb\u2026 [+2241 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "Deepak Patel", "title": "Rework trade margin plan on medical devices: PMO to Niti Aayog", "description": "Association of Indian Medical Device Industry (AIMED), which represents Indian medical device companies, wrote a letter to PMO on August 27 stating that \u201cnot only retailers and hospitals\u201d but the importers too \u201cenjoy irrational margins in the supply chain\u201d.", "url": "https://indianexpress.com/article/business/economy/rework-trade-margin-plan-on-medical-devices-pmo-to-niti-aayog-5358410/", "urlToImage": "https://images.indianexpress.com/2018/08/modi-delhi-ie.jpg?w=759", "publishedAt": "2018-09-15T19:25:00Z", "content": "Written by Deepak Patel | New Delhi | Published: September 16, 2018 12:55:00 am The Niti Aayog has been asked, therefore, to rework on their trade margin model and bring it back. The Prime Minister\u2019s Office (PMO) has rejected the Niti Aayog proposal to implem\u2026 [+3344 chars]"}, {"source": {"id": "reuters", "name": "Reuters"}, "author": "Reuters Editorial", "title": "India bans 328 combination drugs in setback for pharma companies", "description": "The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines.", "url": "https://www.reuters.com/article/us-india-health-drugs/india-bans-328-combination-drugs-in-setback-for-pharma-companies-idUSKCN1LT155", "urlToImage": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "publishedAt": "2018-09-13T08:39:28Z", "content": "NEW DELHI (Reuters) - The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicin\u2026 [+2034 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "Special Correspondent", "title": "NORD plans to set up assembling plant in State", "description": "Markets in India have big scope: MD", "url": "https://www.thehindu.com/news/cities/Visakhapatnam/nord-plans-to-set-up-assembling-plant-in-state/article24897488.ece", "urlToImage": "https://www.thehindu.com/static/theme/default/base/img/og-image.jpg", "publishedAt": "2018-09-07T19:31:40Z", "content": "Mechanical and electrical solutions manufacturer NORD Drive Systems, a subsidiary of Germany-based Getriebebau NORD, organised an end-user service conference and a road show, in association with the AP Chambers of Commerce and Industry Federation (APCCIF) her\u2026 [+1092 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Lupin to train over 1,000 graduates for pharma industry by 2020", "description": "Lupin has launched its #39;Learn and Earn#39; initiative in which candidate who has passed Standard 12 in the science stream with a minimum of 50 percent marks but are facing financial constraints are taken for three-year-long course during which they are pai\u2026", "url": "https://www.moneycontrol.com/news/business/lupin-to-train-over-1000-graduates-for-pharma-industry-by-2020-2924881.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2018/07/Lupin-770x433.jpg", "publishedAt": "2018-09-06T10:46:05Z", "content": "Pharmceutical giant, Lupin Limited expects to train more than 1,000 under graduates into pharma professionals by the year 2020 under its Learn and Earn Initiative, a senior company official said today. Lupin has launched its 'Learn and Earn' initiative in whi\u2026 [+1850 chars]"}, {"source": {"id": null, "name": "Insightsonindia.com"}, "author": "InsightsIAS", "title": "Insights into Editorial: Biosimilars need huge investments, longer timelines", "description": "Insights into Editorial: Biosimilars need huge investments, longer timelines What are Biosimilars? A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are \u2026", "url": "http://www.insightsonindia.com/2018/09/07/insights-into-editorial-biosimilars-need-huge-investments-longer-timelines/", "urlToImage": "http://www.insightsonindia.com/wp-content/uploads/2018/09/editorial-2.jpg", "publishedAt": "2018-09-07T03:41:45Z", "content": "Insights into Editorial: Biosimilars need huge investments, longer timelines What are Biosimilars? A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are \u2026 [+5142 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "Jimeet Modi", "title": "'Towards correction and selective profit taking'", "description": "Uncertainty is likely to persist and the downward drift might not ease anytime soon.", "url": "https://economictimes.indiatimes.com/markets/stocks/news/journey-towards-correction-begins-its-time-for-selective-profit-taking/articleshow/65729453.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65729478,width-1070,height-580,imgsize-53614,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-08T05:33:34Z", "content": "Mr Market finally made a top during the week gone by and started correcting in response to the local and global tailwinds, primarily due to a strengthening dollar, growing current account deficit, inflationary expectations, global tightening and worsening geo\u2026 [+3224 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "N. RAVI KUMAR", "title": "Pharma tech upgrade scheme to get financial partner soon", "description": "SMEs will be get interest subvention upto 6% under PTUAS", "url": "https://www.thehindu.com/news/national/telangana/pharma-tech-upgrade-scheme-to-get-financial-partner-soon/article24958075.ece", "urlToImage": "https://www.thehindu.com/static/theme/default/base/img/og-image.jpg", "publishedAt": "2018-09-15T18:08:33Z", "content": "The Department of Pharmaceuticals will soon initiate the process to select a financial institution for implementing the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) for small and medium enterprises. Expression of interest to select the publ\u2026 [+2506 chars]"}, {"source": {"id": null, "name": "Dailycaller.com"}, "author": "Mark Anthony", "title": "Drug Proposal Could Be Major Job Creator In India, China", "description": "Experts say American consumers may end up facing increased risks when buying medicines", "url": "https://dailycaller.com/2018/09/06/major-job-creator-in-india-china/", "urlToImage": "https://cdn01.dailycaller.com/wp-content/uploads/2018/09/1004465254-594x594-e1536261929709.jpg", "publishedAt": "2018-09-06T19:25:48Z", "content": "Drug companies in India and China are drooling over the prospect that many American jobs in the pharmaceutical industry could soon be outsourced overseas. The reason? A recent announcement from the U.S. Food and Drug Administration (FDA) that it is exploring \u2026 [+3702 chars]"}, {"source": {"id": null, "name": "Acs.org"}, "author": "nobody@acs.org(\"Rick Mullin\"), Rick Mullin", "title": "The rise and fall of the U.S. pharmaceutical chemical maker", "description": "A string of acquisitions has nearly cleared North America of independent drug-service companies", "url": "https://cen.acs.org/business/outsourcing/rise-fall-US-pharmaceutical-chemical/96/i37?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+cen_latestnews+%28Chemical+%26+Engineering+News%3A+Latest+News%29", "urlToImage": "https://cen.acs.org/content/dam/cen/96/37/09637-feature2-glunz.jpg", "publishedAt": "2018-09-16T14:08:59Z", "content": "News this year of the sale of PCI Synthesis and Ampac Fine Chemicals to French and South Korean companies, respectively, came as something of a surprise. Both drug contract manufacturing organizations (CMOs) had been doing well, investing in growth and honing\u2026 [+10446 chars]"}, {"source": {"id": null, "name": "Channelnewsasia.com"}, "author": null, "title": "India bans 328 combination drugs in setback for pharma companies", "description": "NEW DELHI: The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Ind\u2026", "url": "https://www.channelnewsasia.com/news/asia/india-bans-328-combination-drugs-in-setback-for-pharma-companies-10717982", "urlToImage": "http://www.channelnewsasia.com/image/10102260/16x9/991/557/4d1de7be91072f792c7176fba6c7b2c6/Ho/asia-new-default-image.png", "publishedAt": "2018-09-13T08:41:27Z", "content": "NEW DELHI: The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Ind\u2026 [+2069 chars]"}, {"source": {"id": null, "name": "Tribune.com.pk"}, "author": "Reuters, Hasnaat Mailk, Our Correspondent, Our Correspondent, Our Correspondent, Entertainment Desk, Reuters, Reuters, Rahul Aijaz", "title": "India bans 328 combination drugs in setback for pharma companies", "description": "Indian government had in 2016 banned about 350 such drugs The post India bans 328 combination drugs in setback for pharma companies appeared first on The Express Tribune.", "url": "https://tribune.com.pk/story/1802287/3-india-bans-328-combination-drugs-setback-pharma-companies/", "urlToImage": "https://c.tribune.com.pk/2018/09/1802287-pillsmedicinedrugsxcopyx-1536831784-675-640x480.jpg", "publishedAt": "2018-09-13T09:49:23Z", "content": "India bans 328 combination drugs. PHOTO: AFP NEW DELHI: The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resis\u2026 [+2134 chars]"}, {"source": {"id": null, "name": "Tribune.com.pk"}, "author": "Our Correspondent, Our Correspondent", "title": "Deals worth $250m inked at exhibition", "description": "Mutual agreements worth nearly $250 million have been signed at health exhibition The post Deals worth $250m inked at exhibition appeared first on The Express Tribune.", "url": "https://tribune.com.pk/story/1802722/2-deals-worth-250m-inked-exhibition/", "urlToImage": "https://c.tribune.com.pk/2018/09/1802722-pillsmedicinedrugsxcopyx-1536898787-595-640x480.jpg", "publishedAt": "2018-09-14T04:20:27Z", "content": "Representational image. PHOTO: AFP KARACHI: Mutual agreements worth nearly $250 million have been signed at the three-day 15th health and pharmaceutical international exhibition, which ended on Thursday. The exhibition was jointly organised by E-Commerce Gate\u2026 [+918 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Opinion | Why Indian pharmacies should regulate themselves before regulation is forced upon them", "description": "A fair and competitive market system is not only critical for lower prices, product innovation and consumer welfare, but even for the legitimacy of industry. Enlightened self-regulation today may help avoid the costly over-regulation tomorrow.", "url": "https://www.moneycontrol.com/news/business/economy/opinion-why-trade-bodies-should-regulate-themselves-before-regulation-is-forced-upon-them-2949991.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2018/06/Answer-11-1-770x433.jpg", "publishedAt": "2018-09-17T05:20:16Z", "content": "Avinash M Tripathi Recently, the Competition Commission of India (CCI) imposed penalties on the Federation of Gujarat State Chemists and Druggists Association (FGSCDA) and its district-level affiliates for indulging in collusive behaviour. The FGSCDA joined a\u2026 [+4756 chars]"}, {"source": {"id": null, "name": "Business-standard.com"}, "author": "Business Standard", "title": "Trade deficit narrows to $17.4 billion in August from $18.2 billion in July", "description": "India imported gold worth $3.63 billion in August, with inbound trade shooting up by more than 90 per cent", "url": "https://www.business-standard.com/article/economy-policy/trade-deficit-narrows-to-17-4-billion-in-august-from-18-2-billion-in-july-118091401242_1.html", "urlToImage": "https://bsmedia.business-standard.com/_media/bs/img/article/2018-07/06/full/1530900487-7078.jpg", "publishedAt": "2018-09-14T17:55:00Z", "content": "A faster rise in exports and slightly slower growth in inbound shipments led to India\u2019s trade deficit reducing in August from a six-month high in July. The trade deficit in August was $17.4 billion, compared to $18.2 billion in July. This was due to slower gr\u2026 [+2981 chars]"}, {"source": {"id": null, "name": "Livemint.com"}, "author": "Atanu Biswas", "title": "Opinion | The importance of trials in stem cell drugs", "description": "There are self-styled clinics in India offering a range of untested and unproven stem cell drugs", "url": "https://www.livemint.com/Opinion/SEgFFsnMhqRbChyCPw8rfO/Opinion--The-importance-of-trials-in-stem-cell-drugs.html", "urlToImage": "https://www.livemint.com/rf/Image-621x414/LiveMint/Period2/2018/09/13/Photos/Home%20Page/stemcell-kQu--621x414@LiveMint.jpg", "publishedAt": "2018-09-12T17:14:50Z", "content": "The new amendments to the Drugs and Cosmetics Rules of India will be in effect from 13 September. Due to several controversies, allegations of irregularities and protests by health workers against the consent and compensation policies for people undergoing cl\u2026 [+5138 chars]"}, {"source": {"id": null, "name": "Ip-watch.org"}, "author": "Intellectual Property Watch", "title": "Inside Views: Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Undue Monopolies", "description": "The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court. On 28 June, the date of the judgment was set for 6 September. The cancellation occ\u2026", "url": "http://www.ip-watch.org/2018/09/13/brazilian-supreme-court-refuses-judge-biggest-case-ip-access-medicines-benefits-big-pharma-undue-monopolies/", "urlToImage": "http://media.ip-watch.org/weblog/wp-content/uploads/2018/09/Brazil-Carmem-Lucia-w-pharma-300x200.jpg?6e9db4", "publishedAt": "2018-09-13T13:55:56Z", "content": "By Marcela Foga\u00e7a Vieira and Pedro Villardi The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court. On 28 June, the date of the judgment w\u2026 [+15719 chars]"}, {"source": {"id": null, "name": "Insightsonindia.com"}, "author": "InsightsIAS", "title": "SECURE SYNOPSIS: 04 SEPTEMBER 2018", "description": "SECURE SYNOPSIS: 04 SEPTEMBER 2018 NOTE: Please remember that following \u2018answers\u2019 are NOT \u2018model answers\u2019. They are NOT synopsis too if we go by definition of the term. What we are providing is content that both meets demand of the question and at the same ti\u2026", "url": "http://www.insightsonindia.com/2018/09/10/secure-synopsis-04-september-2018/", "urlToImage": "http://www.insightsonindia.com/wp-content/uploads/2018/09/6-2.jpg", "publishedAt": "2018-09-10T09:24:47Z", "content": "SECURE SYNOPSIS: 04 SEPTEMBER 2018 NOTE: Please remember that following \u2018answers\u2019 are NOT \u2018model answers\u2019. They are NOT synopsis too if we go by definition of the term. What we are providing is content that both meets demand of the question and at the same ti\u2026 [+49807 chars]"}, {"source": {"id": null, "name": "Iasexamportal.com"}, "author": "trainee5", "title": "THE GIST of Editorial for UPSC Exams : 13 September 2018 (The importance of trials in stem cell drugs)", "description": "The importance of trials in stem cell drugs Mains Paper: 2 | Health Prelims level: stem cell drugs Mains level: India offering a range of untested and unproven stem cell drugs. Introduction The Federation of Asian Biotech Associations forecast an annual growt\u2026", "url": "https://iasexamportal.com/editorial-gist/13-09-2018-the-importance-of-trials-in-stem-cell-drugs?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+upscportal+%28IAS+EXAM+PORTAL++-+India%27s+Largest+IAS%2C+IFS%2C+PCS%2C+Civil+Services+Aspirants+Community.%29", "urlToImage": null, "publishedAt": "2018-09-13T11:21:45Z", "content": "The importance of trials in stem cell drugs Mains Paper: 2 | Health Prelims level: stem cell drugs Mains level: India offering a range of untested and unproven stem cell drugs. Introduction The Federation of Asian Biotech Associations forecast an annual growt\u2026 [+4182 chars]"}]}